DK0531539T3 - Frysetørret præparation af monoklonale antistoffer - Google Patents

Frysetørret præparation af monoklonale antistoffer

Info

Publication number
DK0531539T3
DK0531539T3 DK92906211T DK92906211T DK0531539T3 DK 0531539 T3 DK0531539 T3 DK 0531539T3 DK 92906211 T DK92906211 T DK 92906211T DK 92906211 T DK92906211 T DK 92906211T DK 0531539 T3 DK0531539 T3 DK 0531539T3
Authority
DK
Denmark
Prior art keywords
freeze
monoclonal antibodies
dried preparation
dried
preparation
Prior art date
Application number
DK92906211T
Other languages
Danish (da)
English (en)
Inventor
Tamotsu Fukuda
Yukio Shimazaki
Yasuyuki Kuroiwa
Shiro Takagi
Original Assignee
Mitsui Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12663510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0531539(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsui Chemicals Inc filed Critical Mitsui Chemicals Inc
Application granted granted Critical
Publication of DK0531539T3 publication Critical patent/DK0531539T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK92906211T 1991-03-08 1992-02-28 Frysetørret præparation af monoklonale antistoffer DK0531539T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4343191 1991-03-08
PCT/JP1992/000226 WO1992015331A1 (fr) 1991-03-08 1992-02-28 Preparation lyophilisee d'anticorps monoclonaux

Publications (1)

Publication Number Publication Date
DK0531539T3 true DK0531539T3 (da) 1998-10-12

Family

ID=12663510

Family Applications (2)

Application Number Title Priority Date Filing Date
DK92906211T DK0531539T3 (da) 1991-03-08 1992-02-28 Frysetørret præparation af monoklonale antistoffer
DK97120255T DK0841067T3 (da) 1991-03-08 1992-02-28 Frysetørret præparation indeholdende et monoklonalt antistof

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97120255T DK0841067T3 (da) 1991-03-08 1992-02-28 Frysetørret præparation indeholdende et monoklonalt antistof

Country Status (10)

Country Link
US (1) US5908826A (de)
EP (2) EP0531539B1 (de)
JP (1) JPH0565233A (de)
AU (1) AU645187B2 (de)
CA (1) CA2082169A1 (de)
DE (2) DE69225757T2 (de)
DK (2) DK0531539T3 (de)
FI (1) FI924982A0 (de)
NO (1) NO924279L (de)
WO (1) WO1992015331A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
AU716785B2 (en) * 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP3624543B2 (ja) * 1996-05-02 2005-03-02 東ソー株式会社 免疫反応試薬及びその製造方法
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6750330B1 (en) * 1998-05-14 2004-06-15 Ashley Davis Lyophilized tubulins
EP1254666A4 (de) * 1999-12-28 2004-12-22 Chugai Pharmaceutical Co Ltd Stabile antikörper zusammensetzungen und injektions formulierungen
AU2001276737A1 (en) * 2000-08-04 2002-02-18 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
DE602004030451D1 (de) 2003-07-15 2011-01-20 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm-produktion
WO2005035574A1 (ja) 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha IgM高濃度安定化溶液
WO2005035573A1 (ja) * 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液の安定化方法
JPWO2005063291A1 (ja) * 2003-12-25 2007-07-19 麒麟麦酒株式会社 抗体を含有する安定な水性医薬製剤
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
EP3673919A1 (de) 2005-06-14 2020-07-01 Amgen Inc. Selbstpuffernde proteinformulierungen
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2008045373A2 (en) * 2006-10-06 2008-04-17 Amgen Inc. Stable antibody formulations
EP2094247B1 (de) * 2006-10-20 2022-06-29 Amgen Inc. Stabile polypeptid-formulierungen
CA2681743A1 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
EP2403874A1 (de) 2009-03-06 2012-01-11 Genentech, Inc. antikörperformulierung
CA3101298A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
EP3757126A1 (de) 2010-11-05 2020-12-30 Novartis AG Verfahren zur behandlung von psoriasus-arthritis mit il-17 antagonisten
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
JP2012158615A (ja) * 2012-05-28 2012-08-23 Kobayashi Pharmaceutical Co Ltd 還元糖によるタンパク質変性を抑制する方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
TW201618774A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
PT3334747T (pt) 2015-08-13 2023-12-12 Amgen Inc Formulação de gonadotrofina líquida estável
JP6890602B2 (ja) 2015-11-06 2021-06-18 アセルタ ファーマ ビー．ブイ． ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149304A (en) * 1936-04-20 1939-03-07 Sharp & Dohme Inc Lyophilic biologically active substances
SU700132A1 (ru) * 1978-06-30 1979-11-30 Томский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Вакцин И Сывороток Способ получени сухого препарата иммуноглобулина
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
JPS58167518A (ja) * 1982-03-29 1983-10-03 Nippon Sekijiyuujishiya ゼラチン誘導体添加静注用人免疫グロブリンの製造法
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
JPS60146833A (ja) * 1984-01-10 1985-08-02 Green Cross Corp:The モノクロ−ナル抗体製剤
JP2565303B2 (ja) * 1984-05-25 1996-12-18 三井東圧化学株式会社 緑膿菌感染症の予防治療剤
US4650772A (en) * 1984-08-09 1987-03-17 Abbott Laboratories Monoclonal antibody stabilization
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
JPS6178731A (ja) * 1985-05-20 1986-04-22 Green Cross Corp:The 加熱処理免疫グロブリン製剤
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
JP2725041B2 (ja) * 1986-12-15 1998-03-09 三井東圧化学株式会社 ヒトモノクローナル抗体とそれを有効成分とする感染症の予防、治療剤
DE3875852T2 (de) * 1987-08-10 1993-03-18 Miles Inc Gereinigtes igm.
WO1989011298A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Formulation for antibody reagents
EP0465513A1 (de) * 1989-03-27 1992-01-15 Centocor, Inc. Formulierungen zur stabilisierung von igm-antikörpern
JPH0384461A (ja) * 1989-08-28 1991-04-10 Green Cross Corp:The 免疫学的凝集反応試薬及びその製法
JPH0911350A (ja) * 1995-06-30 1997-01-14 Olympus Optical Co Ltd エネルギー硬化型樹脂を用いた光学素子の製造方法

Also Published As

Publication number Publication date
EP0841067A1 (de) 1998-05-13
US5908826A (en) 1999-06-01
CA2082169A1 (en) 1992-09-09
WO1992015331A1 (fr) 1992-09-17
FI924982A (fi) 1992-11-04
DE69225757T2 (de) 1998-12-03
DE69232617T2 (de) 2002-10-31
DE69232617D1 (de) 2002-06-27
NO924279D0 (no) 1992-11-06
EP0531539A4 (de) 1995-04-05
EP0531539A1 (de) 1993-03-17
AU645187B2 (en) 1994-01-06
DE69225757D1 (de) 1998-07-09
DK0841067T3 (da) 2002-07-15
AU1337592A (en) 1992-10-06
FI924982A0 (fi) 1992-11-04
JPH0565233A (ja) 1993-03-19
EP0531539B1 (de) 1998-06-03
NO924279L (no) 1992-11-06
EP0841067B1 (de) 2002-05-22

Similar Documents

Publication Publication Date Title
DK0531539T3 (da) Frysetørret præparation af monoklonale antistoffer
DK0941121T3 (da) Stabile lyofiliserede farmaceutiske præparater af mono- eller polyklonale antistoffer
DK666389A (da) Monoklonalt antistof
DK0592106T3 (da) Overfladeomdannelse af gnaverantistoffer
CY2006001I2 (el) Ανθρωποποιημενο heregulin αντισωμα
IL99363A0 (en) Pharmaceutical compositions comprising homoconjugated monoclonal antibodies
DK38293D0 (da) Fremstilling af proteiner
DK63187D0 (da) Krydsbeskyttende monoklonale antistofpraeparater
NO920523D0 (no) Ige-reseptor-antistoff
DK549688D0 (da) Fremstilling af peptider
DK185988A (da) Anvendelse af antigen
NO915017D0 (no) Monoklonale antistoffer og fremgangsmaate for deres fremstilling
NO177311C (no) Anti-fucosylceramid monoklonalt antistoff
DK717888D0 (da) Monoklonale antistoffer
DK93793D0 (da) Fremgangsmaade til fremstilling af naturlige maelkeproteiner
DK474189A (da) Monoklonalt antistof
DK82592D0 (da) Fremstilling af proteiner
DK413389A (da) Monoklonale antistoffer
ITMI910491A0 (it) Immonotossina da anticorpi monoclonali anti-cds
DK370089A (da) Anti-urokinase monoklonale antistoffer
DK141690D0 (da) Anvendelse af monoklonale antistoffer
NO924803D0 (no) Tumor-relatert monoklonalt antistoff 88bv59
ITMI910660A0 (it) Anticorpi monoclonali come antidoti
NO924137D0 (no) Monoklonale anti-igm-antistoffer, deres fremstilling og anvendelse, og hybridomas for fremstilling av de samme
DK220688D0 (da) Monoklonalt antistof